Cullinan Therapeutics reported Q3 2026 results and outlined upcoming milestones across its T cell engager pipeline. The update follows new velinotamig data in S

Cullinan Therapeutics reported Q3 2026 results and outlined upcoming milestones across its T cell engager pipeline. The update follows new velinotamig data in SLE and FDA/TGA clearance for a global Phase 1/2 trial in autoimmune blood disorders.